Edesa Biotech, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended September 30, 2023. Unless noted, financial amounts are U.S. dollars. The filing is an annual report, not a report for calendar Q4. Edesa is a clinical-stage biopharmaceutical company with no approved products or material product revenue.
Business context and pipeline
- EB05 (paridiprubart): The company’s lead anti-TLR4 antibody candidate for acute respiratory distress syndrome (ARDS). A Phase 3 study in severely ill hospitalized COVID-19 patients with ARDS was recruiting; the protocol calls for approximately 600 evaluable subjects and a 28-day mortality primary endpoint. The company was considering an all-cause ARDS approach as well.
- EB01 (daniluromer): Topical candidate for chronic allergic contact dermatitis (ACD). In November 2023, after year-end, Edesa reported Phase 2b results: the 1.0% cream improved the primary symptom measure by 60% versus 40% for placebo (p=0.027); 53% versus 29% met the key secondary endpoint (p=0.048). The 2.0% and 0.2% formulations did not significantly outperform placebo. The company was assessing funding and partnership options.
- EB06: Health Canada approved a future Phase 2 study in moderate-to-severe nonsegmental vitiligo; funding and study initiation remained to be addressed.
- EB07: The company was preparing a U.S. IND for a potential study in fibrotic diseases, including systemic sclerosis. EB02, a potential hemorrhoids treatment, had Health Canada approval for an exploratory Phase 2a study, but timing was under evaluation.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Research and development expense | $4.8 million | $13.3 million |
| General and administrative expense | $4.4 million | $5.0 million |
| Operating loss | $9.2 million | $18.4 million |
| Net loss | $8.4 million | $17.5 million |
| Basic and diluted loss per share | $2.93 | $8.37 |
| Net cash used in operating activities | $6.6 million | $12.3 million |
- No product revenue was reported. Other income included $0.58 million of reimbursement grant income and $0.29 million of interest income; foreign exchange loss was approximately $22,000. These items reduced the net loss but did not represent product sales.
- Operating expenses fell $9.2 million, principally because of lower external R&D and manufacturing costs, including a prior-year $2.5 million bulk drug purchase, and lower noncash share-based compensation. The lower loss therefore reflected reduced spending, not demonstrated commercial profitability.
- At September 30, 2023, cash and cash equivalents were $5.36 million; working capital was $4.6 million; total current assets were $6.44 million and current liabilities were $1.82 million. Total liabilities were $1.84 million, with no funded debt reported at fiscal year-end. Accumulated deficit was $52.4 million.
- Management said available cash and expected ATM proceeds, credit-facility advances and Canadian government reimbursements were sufficient for at least 12 months. Edesa nevertheless expects continuing losses and may need additional financing.
Material changes, outlook and notable items
- Operating cash use declined from $12.3 million to $6.6 million, while financing cash provided declined from $11.6 million to $4.8 million. Cash decreased by $1.73 million during FY2023.
- In October 2023, Canada’s Strategic Innovation Fund (SIF) committed up to C$23 million for EB05 development, regulatory work, manufacturing scale-up and nonclinical safety studies. Up to C$5.75 million is nonrepayable; the remaining C$17.25 million is conditionally repayable beginning in 2029 only if Edesa earns gross revenue, subject to the agreement’s terms and covenants. The project is to be completed by December 31, 2025. Funding can be suspended or repayment demanded in specified default circumstances.
- In October 2023, Edesa entered an unsecured revolving credit arrangement with an entity controlled by its CEO. The immediately available credit limit was $3.5 million, within a stated facility of up to $10 million; borrowing is limited by an eligible-receivables borrowing base. The rate is CIBC U.S. Base-Interest Rate plus 3%, and a 1.5% annual standby fee applies to unused availability. No funds had been drawn as of the filing’s stated subsequent-event disclosure.
- The Canaccord at-the-market program had approximately $7.1 million of available capacity at year-end, subject to offering limitations. FY2023 ATM sales generated approximately $1.1 million net; subsequent sales through the filing date generated approximately $0.3 million net. Equity issuance may dilute shareholders.
- After year-end, Edesa effected a one-for-seven reverse share split and reported that Nasdaq had confirmed restored compliance with its minimum bid-price rule. The company reported 3,164,722 common shares outstanding as of December 13, 2023.
- Key risks include reliance on additional capital and grants, uncertain clinical and regulatory outcomes, Phase 3 enrollment and execution, dependence on third-party manufacturers and clinical-trial providers, competition, potential dilution, and the possibility that licensed intellectual property or funding agreements could be terminated or require repayment. The company also disclosed related-party arrangements, including the CEO-controlled credit facility and office lease.
Most important facts for investors to verify
- Current EB05 Phase 3 enrollment, site activation, protocol status and funding availability, including compliance with SIF covenants and the December 2025 project deadline.
- Whether the reported EB01 Phase 2b findings are confirmed in complete study data and support a funded next-stage development plan or partnership.
- Current cash runway, actual operating cash burn, remaining ATM capacity, credit borrowing-base availability and any subsequent financing or share-count changes.
- Terms, utilization and governance of the CEO-controlled credit facility, including standby fees, related-party approvals and any future advances.
- Clinical, regulatory and financing plans and required funding for EB06, EB07 and EB02; none had an active efficacy-stage program described as underway in this filing.